JPWO2021123142A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021123142A5 JPWO2021123142A5 JP2022535637A JP2022535637A JPWO2021123142A5 JP WO2021123142 A5 JPWO2021123142 A5 JP WO2021123142A5 JP 2022535637 A JP2022535637 A JP 2022535637A JP 2022535637 A JP2022535637 A JP 2022535637A JP WO2021123142 A5 JPWO2021123142 A5 JP WO2021123142A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- neovascularization
- pharmaceutically acceptable
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030533 eye disease Diseases 0.000 claims 6
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010065630 Iris neovascularisation Diseases 0.000 claims 2
- 241001111421 Pannus Species 0.000 claims 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 229960002833 aflibercept Drugs 0.000 claims 2
- 108010081667 aflibercept Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 210000004240 ciliary body Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 108700036276 KH902 fusion Proteins 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 108010043116 abicipar pegol Proteins 0.000 claims 1
- 229950008281 abicipar pegol Drugs 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950000025 brolucizumab Drugs 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229950005748 conbercept Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940116862 faricimab Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Claims (12)
- 化学式(I):
ここでR1がクロロ、R2がエチルまたは水素、およびR3が水素であり;
角膜内血管新生、虹彩血管新生、毛様体血管新生、角膜パンヌス、脈絡膜血管新生、網膜血管新生、滲出型加齢性黄斑変性症、増殖性糖尿病網膜症、未熟児網膜症、および虚血性視神経症から成る群から選択される眼疾患または眼障害の治療に用いる、組成物。 - 請求項1に記載の用途の組成物であって、ここで該化合物がラキニモドまたは薬学的に許容可能なその塩である、組成物。
- 請求項1に記載の用途の組成物であって、ここで該化合物が化学式(IV):
- 請求項1~3のいずれか1項に記載の用途の組成物であって、ここで該眼疾患または眼障害が、角膜内血管新生、虹彩血管新生、毛様体血管新生、および角膜パンヌスから成る群から選択される、組成物。
- 請求項1~3のいずれか1項に記載の用途の組成物であって、ここで該眼疾患または眼障害が、増殖性糖尿病網膜症、未熟児網膜症、および虚血性視神経症から成る群から選択される、組成物。
- 請求項1~3のいずれか1項に記載の用途の組成物であって、ここで該眼疾患または眼障害が、脈絡膜血管新生、網膜血管新生、および滲出型加齢性黄斑変性症から成る群から選択される、組成物。
- 請求項6に記載の用途の組成物であって、ここで該眼疾患または眼障害が滲出型加齢性黄斑変性症である、組成物。
- 請求項1~7のいずれか1項に記載の用途の組成物であって、ここで該組成物がアフリベルセプトを含む血管形成阻害剤を含む、あるいは該組成物を、アフリベルセプトを含む血管形成阻害剤と組み合わせて投与する、組成物。
- 請求項1~8のいずれか1項に記載の用途の組成物であって、ここで該組成物がVEGF阻害剤を含む、あるいは該組成物をVEGF阻害剤と組み合わせて投与する、組成物。
- 請求項9に記載の用途の組成物であって、ここで該VEGF阻害剤が、アフリベルセプト、ラニビズマブ、ベバシズマブ、ブロルシズマブ、アビシパル・ペゴル(abicipar pegol)、コンバーセプト、およびファリシマブから成る群から選択される、組成物。
- 請求項1~10のいずれか1項に記載の用途の組成物であって、ここで該組成物が少なくとも1種類の薬学的に許容可能な賦形剤を含む、あるいは該組成物を少なくとも1種類の薬学的に許容可能な賦形剤と組み合わせて投与する、組成物。
- 請求項1~11のいずれか1項に記載の用途の組成物であって、ここで該投与経路が、局所、経口、硝子体内、結膜下、眼球後部、前房内、または全身性である、組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19218062 | 2019-12-19 | ||
EP19218062.8 | 2019-12-19 | ||
EP20156158.6 | 2020-02-07 | ||
EP20156158 | 2020-02-07 | ||
PCT/EP2020/086993 WO2021123142A1 (en) | 2019-12-19 | 2020-12-18 | Compounds for treatment of eye diseases associated with excessive vascularisation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023509336A JP2023509336A (ja) | 2023-03-08 |
JPWO2021123142A5 true JPWO2021123142A5 (ja) | 2023-12-26 |
Family
ID=74141502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022535637A Pending JP2023509336A (ja) | 2019-12-19 | 2020-12-18 | 過剰血管新生に関連する眼疾患を治療する化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11478465B2 (ja) |
EP (2) | EP3886858B1 (ja) |
JP (1) | JP2023509336A (ja) |
KR (1) | KR20220118419A (ja) |
CN (1) | CN114845718A (ja) |
AU (1) | AU2020408179A1 (ja) |
BR (1) | BR112022009192A2 (ja) |
CA (1) | CA3157394A1 (ja) |
DK (1) | DK3886858T3 (ja) |
ES (1) | ES2921360T3 (ja) |
IL (1) | IL293469B2 (ja) |
MX (1) | MX2022006439A (ja) |
PL (1) | PL3886858T3 (ja) |
WO (1) | WO2021123142A1 (ja) |
ZA (1) | ZA202204939B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4312986A1 (en) | 2021-04-01 | 2024-02-07 | Active Biotech AB | Laquinimod formulation for ocular use |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
EP2376456A2 (en) | 2008-12-17 | 2011-10-19 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
EP3213636A1 (en) * | 2010-07-09 | 2017-09-06 | Teva Pharmaceutical Industries, Ltd. | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
BR112014002095A2 (pt) | 2011-07-28 | 2017-02-21 | Teva Pharma | tratamento de esclerose múltipla com combinação de laquinimod e acetato de glatiramer |
TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
CN104884049A (zh) * | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
WO2015060812A1 (en) | 2013-10-21 | 2015-04-30 | Howard University | Treating ocular disease with efflux transporter inhibitors |
WO2015095772A2 (en) * | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
WO2017120355A1 (en) | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
AU2018302022A1 (en) * | 2017-07-17 | 2020-02-27 | Macregen, Inc. | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
SG11202005799XA (en) | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
KR20200109316A (ko) | 2017-12-22 | 2020-09-22 | 케모센트릭스, 인크. | C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물 |
US11608336B2 (en) | 2018-04-02 | 2023-03-21 | Chemocentryx, Inc. | Prodrugs of fused-bicyclic C5aR antagonists |
-
2020
- 2020-12-18 DK DK20838435.4T patent/DK3886858T3/da active
- 2020-12-18 CA CA3157394A patent/CA3157394A1/en active Pending
- 2020-12-18 JP JP2022535637A patent/JP2023509336A/ja active Pending
- 2020-12-18 PL PL20838435.4T patent/PL3886858T3/pl unknown
- 2020-12-18 ES ES20838435T patent/ES2921360T3/es active Active
- 2020-12-18 WO PCT/EP2020/086993 patent/WO2021123142A1/en active Application Filing
- 2020-12-18 AU AU2020408179A patent/AU2020408179A1/en active Pending
- 2020-12-18 EP EP20838435.4A patent/EP3886858B1/en active Active
- 2020-12-18 MX MX2022006439A patent/MX2022006439A/es unknown
- 2020-12-18 IL IL293469A patent/IL293469B2/en unknown
- 2020-12-18 BR BR112022009192A patent/BR112022009192A2/pt unknown
- 2020-12-18 EP EP22167643.0A patent/EP4094765A1/en active Pending
- 2020-12-18 CN CN202080087752.XA patent/CN114845718A/zh active Pending
- 2020-12-18 KR KR1020227019983A patent/KR20220118419A/ko unknown
-
2021
- 2021-07-02 US US17/366,979 patent/US11478465B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04939A patent/ZA202204939B/en unknown
- 2022-09-07 US US17/939,109 patent/US20230066364A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023071798A5 (ja) | ||
JP5180834B2 (ja) | 治療方法 | |
US20160339005A1 (en) | Compositions and methods for treating ocular diseases | |
JP2019131569A5 (ja) | ||
JP2017514917A5 (ja) | ||
JP2017503835A5 (ja) | ||
JP2021119158A5 (ja) | ||
WO2010015672A1 (en) | Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye | |
WO2017002941A1 (ja) | クエン酸エステルを含有するデポ剤 | |
JP2013528607A5 (ja) | ||
JP2013510852A5 (ja) | ||
JPWO2021123142A5 (ja) | ||
JP2024519629A (ja) | 血管新生性眼疾患の治療のための長期の高用量vegfアンタゴニストレジメン | |
JP2017527600A5 (ja) | ||
US20220306732A1 (en) | Modified dosing of vegf inhibitors for ophthalmic use | |
RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
JP2020530459A5 (ja) | ||
JP2004520267A (ja) | ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法 | |
JP2021138710A5 (ja) | ||
JP2013513606A5 (ja) | ||
JP2018536650A5 (ja) | ||
JP2005525408A5 (ja) | ||
JPWO2021021909A5 (ja) | ||
JP2013523748A5 (ja) | ||
JP2010260857A (ja) | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 |